The Treatment Action Group Pipeline Report provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV) and tuberculosis (TB).
Read the report on the Treatment Action Group website.
There are more biomedical strategies available for HIV prevention than ever before. At the same time, research is continuing. Trials must be able to test new tools and meet ethical standards by providing participants with the best available prevention package.
No Data No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities, written and informed by trans and gender-diverse (TGD) activists from Cape Town to Berlin, with support and solidarity from AVAC, offers practical and essential priorities for demonstrable and viable HIV interventions for TGD people.
This manifesto reflects the urgent need for peer-led HIV prevention research with true ownership and acceptability in TGD communities.
Also available: download the Manifesto summary for a snapshot of key recommendations
The AMP trials evaluated the ability of a broadly neutralizing antibody (bNAb), called VRC01, to protect against HIV. The trials showed that VRC01 did not reduce the overall risk of acquiring HIV. However, VRC01 protected some individuals from infection by HIV viruses that were particularly vulnerable or “sensitive” to the antibody. Together these results mean AMP will inform future bNAb and vaccine studies. Read Understanding Results to learn more.
The authors recommend research ethics committees (RECs) amend their application forms to better ‘trigger’ researchers to thoughtfully plan sound stakeholder engagement. In the longer term, RECs’ documents should be better harmonised internally regarding their stance on stakeholder engagement.
This document is a new tool to help guide stakeholder engagement in COVID-19 research. Built from the Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials (GPP), this document responds to needs expressed by both researchers and advocates as the world watched COVID-19 research progress with unprecedented speed and urgency.
A resource to support advocacy for multipurpose prevention technologies (MPTs). The Guide calls out four areas ripe for advocate involvement. It also provides a snapshot on the status of MPT research and development and data on investments—critical information that can support evidence-based advocacy.
A 2021 update to the WHO recommendations on HIV clinical and service delivery of prevention and treatment.
Internal condoms, previously called female condoms, are an important tool to advance sexual and reproductive health and rights (SRHR) for all. Internal condoms are currently the only non-hormonal multipurpose prevention method designed for and initiated by women and receptive sexual partners that provides effective protection against unintended pregnancy and STI acquisition, including HIV. This resource shares new data on the efficacy and importance of internal condoms, and includes critical new USAID condom procurement data that indicate the need for increased internal condom procurement by United States global health agencies and programs.
UNAIDS and the World Health Organization have published this updated guidance on ethical considerations in HIV prevention trials. The new guidance is the result of a year-long process that saw more than 80 experts and members of the public give inputs and is published 21 years after the first edition appeared.